Cipher Mining Inc vs TG Therapeutics Inc — how do they compare? Cipher Mining Inc trades at $19.88 (market cap $8.13B), while TG Therapeutics Inc trades at $56.05 (market cap $8.41B). The key difference: Cipher Mining Inc and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Cipher Mining Inc nearer its low. Which is the better fit depends on your goals.
| CIFR | TGTX | |
|---|---|---|
Market Cap | $8.13B | $8.41B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $59.06 |
52-Week Low | $4.72 | $26.39 |
Enterprise Value | $12.16B | $8.65B |
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $20.085, down 9.16% over 24 hours, reflecting bearish technical signals despite unanimous analyst buy ratings. The company is transitioning from Bitcoin mining to AI data center operations, evidenced by a $11.4B contracted revenue backlog but faces significant financial strain with a -427.79% net income margin and negative cash flow from operations. Recent news highlights volatility driven by AI infrastructure developments and capital raises.
The outlook hinges on successful execution of its AI data center pivot, offering substantial upside to the $32.81 consensus price target, but high valuation multiples and persistent losses pose near-term risks. Investors must weigh transformative growth potential against cash burn and execution challenges in a competitive sector.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Trailing returns across standard periods
Latest headlines on both assets
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →